1. |
Cooperative group cancer trials satisfy uncertainty principle |
|
Inpharma Weekly,
Volume &NA;,
Issue 1444,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
2. |
Keeping cost-utility and clinical trial results together ideal |
|
Inpharma Weekly,
Volume &NA;,
Issue 1444,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
3. |
Patients' nonadherence to antipsychotic medication appears to exhibit a consistent association with greater costs, |
|
Inpharma Weekly,
Volume &NA;,
Issue 1444,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
4. |
Insulin analogues worth the extra cost in type 1 DM |
|
Inpharma Weekly,
Volume &NA;,
Issue 1444,
2004,
Page 5-6
L Everitt,
Preview
|
|
摘要:
Type 1 diabetes mellitus (DM) imposes a heavy toll on society, due to its high prevalence and mortality, and the acute and chronic complications associated with it. At the 64th annual scientific sessions of the American Diabetes Association (ADA) [Orlando, Florida, US; Jun 2004], a team of researchers from Switzerland and Denmark showed that although insulin detemir plus insulin aspart cost more than NPH insulin [insulin suspension isophane] plus soluble human insulin in patients with type 1 DM, glycaemic control improved and there was a reduction in hypoglycaemic events and body mass index (BMI) among recipients of the former therapy.1A second study presented at the conference by investigators from the US and Spain revealed that the insulin analogue insulin glargine was also good value for money compared with NPH insulin.2
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
5. |
Improving uptake of breast cancer screening worth it in the US? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1444,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
6. |
Value of donepezil doubtful in Alzheimer's disease |
|
Inpharma Weekly,
Volume &NA;,
Issue 1444,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
7. |
'HAMLET' therapy for papillomas: to be or not to be? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1444,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
8. |
Erlotinib prolongs survival in advanced, refractory NSCLC |
|
Inpharma Weekly,
Volume &NA;,
Issue 1444,
2004,
Page 9-10
MI Wilde,
Preview
|
|
摘要:
Erlotinib [Tarceva; OSI 774] is the first epidermal growth factor receptor (EGFR)-targeted anticancer agent to significantly prolong survival in patients with non-small-cell lung cancer (NSCLC), according to a study presented at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO) [New Orleans, US; June 2004]. In a phase III study involving over 700 patients with advanced NSCLC whose disease had progressed despite first- or second-line chemotherapy, overall and progression-free survival durations, time to deterioration of symptoms and response rate were significantly improved in erlotinib, compared with placebo, recipients.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
9. |
Trospium chloride improves overactive bladder symptoms in patients with urge incontinence, |
|
Inpharma Weekly,
Volume &NA;,
Issue 1444,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
10. |
Pegfilgrastim [Neulasta] may lower the incidence of infection in patients with breast cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1444,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|